Wolfe Research Initiates Coverage On Hilton Worldwide Holdings with Peer Perform Rating
Wolfe Research analyst Peter Supino initiates coverage on Hilton Worldwide Holdings (NYSE:HLT) with a Peer Perform rating.
Read original at benzingaStocks · News reference
A Congress Member Sold Up To $15K In Viasat Stock: Here's What You Need To Know
A September filing shows that Representative Jonathan Jackson reported a sale in Viasat (NASDAQ:VSAT), valued between $1,001 and $15,000. The transaction date is listed as August 28, 2026, with the report published on
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Susquehanna Maintains Neutral on Hilton Worldwide Holdings, Lowers Price Target to $345
Susquehanna analyst Christopher Stathoulopoulos maintains Hilton Worldwide Holdings (NYSE:HLT) with a Neutral and lowers the price target from $353 to $345.
Read original at benzingaWhat Does a Hilton Executive's Sale of Nearly 2,000 Shares Mean for Investors?
Hilton Worldwide Holdings' Chief Development Officer Christian Charnaux sold 1,854 shares on August 5, 2026, for approximately $601,700. The sale was non-discretionary and executed solely to cover tax obligations from equity award vesting, not reflecting any negative view on the stock. Charnaux retained 16,435 shares worth $5.3 million, maintaining significant alignment with shareholders. The transaction is not a cause for investor concern given Hilton's strong Q2 performance with revenue growth and improved earnings guidance.
Read original at the-motley-foolAbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.
Read original at the-motley-foolIs Generics Still a Quiet Profit Engine for Cardinal Health?
Cardinal Health's generics business continues to be a steady profit contributor, with fiscal 2026 volume growth exceeding long-term planning assumptions of 2-3%. The company expects fiscal 2027 to benefit from new generic launches, brand-to-generic conversions, and stable Red Oak program dynamics, supporting projected Pharma segment profit growth of 8-11%. Peers McKesson and Cencora also show strength in their pharmaceutical distribution and generics portfolios.
Read original at zacks-investment-researchHere's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today
A $1,000 investment in McKesson (MCK) made in September 2016 would be worth $4,795.36 as of September 1, 2026, representing a 379.54% gain and significantly outperforming the S&P 500's 254.05% return. The pharmaceutical distributor is benefiting from growth in specialty pharmaceuticals, oncology services, and GLP-1 medications, with FY26 revenues reaching $403.4 billion and adjusted EPS up 18% year-over-year. Analysts remain optimistic with recent earnings estimate revisions and raised fiscal 2027 guidance.
Read original at zacks-investment-research